Cargando…

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies

Detalles Bibliográficos
Autores principales:	Puttagunta, Sailaja, Boucher, Helen, Talbot, George, Wilcox, Mark, Dunne, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781625/ http://dx.doi.org/10.1093/ofid/ofu052.132

Ejemplares similares

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
por: Dunne, Michael W, et al.
Publicado: (2015)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

398 Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures
por: Baldassarre, James, et al.
Publicado: (2014)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

1652 Retrospective Comparision of Oral Vancomycin Capsules vs Oral Vancomycin Solution for the Treatment of Severe Clostridium Defficile Infection
por: Saleh, Rania, et al.
Publicado: (2014)

673 Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2014)

To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
por: Freshwater, Dustin, et al.
Publicado: (2017)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

1651 Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals
por: Bai, Francesca, et al.
Publicado: (2023)

799 Linezolid vs Vancomycin in the Treatment of Nosocomial Pneumonia: A Cost-effectiveness Analysis Incorporating Results from the ZEPHyR Trial
por: Collins, Curtis, et al.
Publicado: (2014)

466 Skin lesions in febrile neutropenic patients
por: Yemisen, Mucahit, et al.
Publicado: (2014)

393 Vancomycin Dosing in Obese Patients
por: Alquwaizani, Mohammed, et al.
Publicado: (2014)

674 Comparison of the Microbiology and Antibiotic Treatment between Diabetic and Non-Diabetic Patients Hospitalized with Acute Bacterial Skin and Skin Structure Infection
por: Jenkins, Timothy, et al.
Publicado: (2014)

413 In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Skin and Skin Structure Infections in the United States – TEST 2011-2013
por: Hackel, Meredith, et al.
Publicado: (2014)

396 What is the Best Predictor for Vancomycin Nephrotoxicity?
por: Hammoud, Kassem, et al.
Publicado: (2014)

728 Evaluation of Empirical Regimens Including Antistaphylococal Beta-lactam Antibiotics vs Vancomycin Monotherapy on Outcomes of Patients with Methicillin-Susceptible Staphylococcus aureus (MSSA) Bacteremia
por: Terico, Adrienne, et al.
Publicado: (2014)

682 Microbiology and Antibiotic Treatment among Injection Drug Users and Non-Injection Drug Users Hospitalized with Acute Bacterial Skin and Skin Structure Infection
por: Jenkins, Timothy, et al.
Publicado: (2014)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

394 Influence of febrile neutropenia on the pharmacokinetics and dosage requirements of vancomycin
por: Shiotsuka, Shouichi, et al.
Publicado: (2014)

262 Effect of NSAID/Corticosteroid Use on the Efficacy of Tedizolid in Acute Bacterial Skin and Skin Structure Infections: Pooled Data From the Phase 3 ESTABLISH-1 and ESTABLISH-2 Studies
por: Sandison, Taylor, et al.
Publicado: (2014)

474 Ceftaroline Salvage Therapy for MRSA Bacteremia Following Vancomycin Failure
por: Pettit, Natasha, et al.
Publicado: (2014)

733 Vancomycin-Resistant Enterococcus (VRE) faecium Bloodstream Infections and Mortality
por: Suleyman, Geehan, et al.
Publicado: (2014)

688 The Effect of Preoperative Vancomycin on Bacteria Isolation from Operative Cultures
por: Young, Heather, et al.
Publicado: (2014)

282 Epidemiology of Skin and Soft-Tissue Infections in US Army Trainees at Fort Benning
por: Ellis, Michael, et al.
Publicado: (2014)

1294 Skin Microbiota Contamination Causes False Positive QuantiFERON-TB Results
por: Gaur, Rajiv
Publicado: (2014)

721 Decreasing Prevalence of Vancomycin-Heteroresistance (hVISA) among Methicillin-Resistant Staphylococcus aureus (MRSA) Blood Isolates over 10 years: Potential Impact of Vancomycin Treatment Guidelines
por: Khatib, Riad, et al.
Publicado: (2014)

392 Vancomycin Dosing and Concentrations at a Large University-Affiliated County Hospital
por: Youn, Gilmer, et al.
Publicado: (2014)

321 Screening Strategy to Detect Vancomycin-Resistant Enterococci Conversion in Exposed Roommates
por: Ng, Wil, et al.
Publicado: (2014)

409 Efficacy of Vancomycin against Biofilms of Neonatal Staphylococcus epidermidis Bloodstream Isolates
por: Simitsopoulou, Maria, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2haj1qlj9baq8vo8d1d8lkpnd9